ガバペンチノイドの乱用と依存に関する医療従事者およびその他の専門家の見解: 定性研究の体系的レビュー
Amy G McNeilage1,2, Evan Browne3, Suzanne Nielsen2
1Sydney Medical School, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.
European journal of pain (London, England)
|September 2, 2025
まとめ
医療従事者は,ガバペンチノイドの誤用が社会的および構造的要因に起因する重大な問題であると報告しています. これらの薬を誤用する患者の 害を軽減し,治療を改善するために 体系的な,証拠に基づいた戦略が必要です.
科学分野:
- 薬理学と公衆衛生
- 質的研究合成
- 依存症 医学
背景:
- 慢性疼痛に対するガバペンチノイドの処方量の増加
- ガバペンチノイドの乱用や依存症に関する懸念が高まっている.
- これらの課題について専門的な見方を理解する必要があります.
研究 の 目的:
- ガバペンチノイドの乱用と依存症に関する医療およびその他の専門家の見解をまとめます.
- 専門的な観点からガバペンチノイドの誤用の原因と兆候を特定する.
- 提案された害を減らす戦略を探求する.
主な方法:
- 19件の研究の質的体系的レビュー
- 2025年5月までの6つの主要データベースを検索した
- 信頼性の評価のためのテーマ統合とGRADE-CERQual.
主要な成果:
- ほとんどの研究は薬物使用と法執行機関からのものです.
- 薬物乱用の原因には 多重薬物使用,オピオイド代用,苦痛,非薬物治療の欠如が挙げられます.
- 専門家は倫理的な緊張を特定し 教育や政策改革などの 害の軽減戦略を提案しました
結論:
- ガバペンチノイドの誤用は,臨床的,社会的,構造的要因によって影響を受けます.
- システム的な反応は極めて重要で,個々の処方箋を超えて広がります.
- オピオイド政策からの教訓は 均衡と思いやりと証拠に基づいた戦略を導くべきです
関連する概念動画
Drug Abuse and Addiction: Pharmacological Phenomena
655
Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not...
655
Drug Dependence
1.2K
Medications are typically administered to achieve therapeutic effects. Some drugs can modify an individual's mood and perception, frequently resulting in various enjoyable experiences. However, this can result in drug dependency, a condition marked by continuous drug use despite potential negative consequences. Drug dependency primarily falls into two categories: psychological and physical dependence. Psychological dependence occurs when the pleasurable feelings induced by the drug...
1.2K
Analgesia and Pain Management
788
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
788
CNS Depressants: Barbiturates and Benzodiazepines
466
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
466
Antiepileptic Drugs: GABAergic Pathway Potentiators
635
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
635
Antiepileptic Drugs: Potassium Channel Activators
274
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
274


